A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy
复制标题
DOI：
10.2337/dc09-2241
复制
发表时间：
2010-07-01
期刊：
影响因子：
16.2
通讯作者：
Bakker, Stephan J. L.
中科院分区：
文献类型：
--
作者：
Alkhalaf, Alaa;Klooster, Astrid;Bakker, Stephan J. L.
研究设计和方法-患有2型糖尿病和UAE相当于15-300 mg/24 h的患者，尽管使用ACE抑制剂（ACE-Is）或血管紧张素受体阻滞剂（ARB），结果：与安慰剂组相比，苯磷硫胺治疗组硫胺素水平明显改善（P < 0.001）。苯磷硫胺治疗没有显着减少24小时UAE或24小时KIM-1 excretion.CONCLUSIONS -在2型糖尿病和肾病患者中，高剂量苯磷硫胺治疗12周，除了ACE-Is或ARB没有减少UAE或KIM-1排泄，尽管改善硫胺素状态。
OBJECTIVE - To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy.RESEARCH DESIGN AND METHODS - Patients with type 2 diabetes and UAE equivalent to 15-300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43).RESULTS - Compared with placebo, benfotiamine treatment resulted in significant improvement of thiamine status (P < 0.001). Benfotiamine treatment did not significantly decrease 24-h UAE or 24-h KIM-1 excretion.CONCLUSIONS - In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status.